A recent article published in MEDPAGE TODAY titled: “Officials Investigate Physician’s Death After COVID Vaccination”1 recounts a case of Immune Thrombocytopenic Purpura (ITP), leading to death, following the administration of a COVID-19 vaccine. ITP is an autoimmune disease that results in depletion of platelets and risk of bleeding. No causal relation has been demonstrated in this case, although several similar cases have been reported.2
The question here is not the relationship between ITP and vaccine, but how ITP is addressed and why patients are still dying from it.
A Discovery Going Back to the 80s
Back in the 80s Dr. Mirko Beljanski, a French biologist working at the Pasteur Institute in Paris France, knew that for any cell to divide, it requires short RNAs, which act as specific initiators of cell proliferation. He developed a preparation of short RNA fragments that function as primers for DNA synthesis in bone marrow stem cells. When these stem cells divide and differentiate they give rise to white blood cells and platelets. Beljanski’s RNA fragments trigger the organism to produce, naturally and in physiological proportions, white blood cells and platelets. These are crucial for our immune defense and blood coagulation.3
“While working at the Pasteur Institute, Beljanski tested his fragments on rabbits given daily intravenous injections of Endoxan, each dose being forty times greater, proportionally in terms of weight, than the dose normally taken by a human in the course of one week. This led to a drop in white blood cells expected to induce death of the animal within ten days. Then, RNA fragments were administered. The leukocyte count rose, and within twenty-four to forty-eight hours was normal again. Once the experiment was finished, the rabbits continued in good health, despite having received antimitotic doses far beyond the doses given in human therapy. Follow-up studies conducted one to two years after the experiment showed no side effects in the rabbits,” narrates his daughter.4
A Clinical Trial in Advanced Cancer Patients
Since 1999 The Beljanski Foundation, a New York based 501(C)(3), has worked toward funding research that could lead to natural approach to cancer. With the support of The Beljanski Foundation, those RNA fragments have since been tested in a Phase I clinical trial at Cancer Treatment Centers of America (CTCA) in advanced cancer patients undergoing chemotherapy. These patients routinely suffer from thrombocytopenia as a consequence of myelosuppressive drugs. Platelets are essential for blood clotting and serious deficiencies can lead to hemorrhage and death. In the trial, patients receiving the RNA fragments were protected from chemotherapy induced thrombocytopenia and did not require chemotherapy dose reduction, suspension of treatment or platelet transfusions. Indeed, this Phase I trial demonstrated efficacy, effective dose and safety, as no adverse events were observed. Those results were published over ten years ago.5
What is the Medical Community Waiting for?
It is therefore legitimate to wonder why this doctor was not given a chance to improve his platelet counts thanks to those RNA fragments, whether or not his thrombocytopenia was a complication from the vaccine he received. And beyond one case, why Beljanski’s RNA fragments are not more widely offered to anyone suffering from ITP.
- Officials Investigate Physician’s Death After COVID Vaccination MedPage Today January 27,2021 https://www.medpagetoday.com/special-reports/exclusives/90917
- A Few COVID Vaccine Recipients Developed a Rare Blood Disorder, Denise Grady, New York Times, Published Feb. 8, 2021. Updated Feb. 10, 2021.
- M. BELJANSKI, ” Overview: BLRs as Inducers of In Vivo Leucocyte and Platelet Genesis “. Deutsche Zeitschrift für Onkologie, 24, 2, 1992, pp. 41-46.
- “Winning the War on Cancer: The Epic Journey Towards a Natural Cure” Sylvie Beljanski, Morgan James Publishing, 2018
- Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia. BMC Cancer 2010 Oct 19;10:565.doi: 10.1186/1471-2407-10-565.